DEER PARK, Ill., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2021 financial and operating results on Monday, August 16, 2021. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 4:30 p.m. ET (3:30 p.m. CT).
Follow this link:
Eton Pharmaceuticals to Report Second Quarter 2021 Financial Results on Monday, August 16, 2021
Related Post
- Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8® - March 18th, 2024
- Nuvectis Pharma to Present at the 36th Annual Roth Conference - March 18th, 2024
- New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia - March 18th, 2024
- Avenue Therapeutics Receives Positive Listing Determination from Nasdaq - March 18th, 2024
- Genmab Announces Initiation of Share Buy-Back Program - March 18th, 2024
- Eupraxia Pharmaceuticals Announces Closing of Overnight Marketed Offering for Gross Proceeds of C$33.9 Million - March 18th, 2024
- AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity - March 18th, 2024
- Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024 - March 18th, 2024
- Scilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered into a Definitive Mutual Release and Settlement Agreement... - March 18th, 2024
- Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer - March 18th, 2024
- Scilex Holding Announces Issuance of Halal Certification for its ZTlido® product by Circle H International, Inc. - March 18th, 2024
- Sanofi: Information concerning the total number of voting rights and shares - February 2024 - March 18th, 2024
- XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps - March 18th, 2024
- NurExone's Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence - March 18th, 2024
- Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results - March 18th, 2024
- Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares - March 18th, 2024
- Financière de Tubize - Annual report 2023 - March 18th, 2024
- Idorsia and Viatris successfully close the transaction for the global research and development collaboration - March 18th, 2024
- Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand - March 18th, 2024
- Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed - March 18th, 2024
- Pharvaris Announces Extraordinary Meeting of Shareholders - February 18th, 2024
- EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - February 18th, 2024
- XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right - February 18th, 2024
- Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024 - February 18th, 2024
- Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent... - February 18th, 2024
- Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results - February 18th, 2024
- Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering - February 18th, 2024
- Intelligent Bio Solutions Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement and Confirms Compliance with Minimum Stockholders’... - February 18th, 2024
- Mdxhealth Announces Resignation of Board Member - February 18th, 2024
- Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020... - February 18th, 2024
- ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2023 - February 18th, 2024
- FDA approves Xolair as first and only medicine for children and adults with one or more food allergies - February 18th, 2024
- Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma - February 18th, 2024
- Iovance Biotherapeutics to Host Conference Call and Webcast on Friday, February 16, 2024 - February 18th, 2024
- Motus GI Holdings, Inc. Announces Adjournment of the February 16, 2024 Special Meeting of Stockholders - February 18th, 2024
- Lifecore Biomedical, Inc. Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal - February 18th, 2024
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - February 18th, 2024
- Soleno Therapeutics Strengthens Leadership Team with Key Appointments - January 25th, 2024
- CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a... - January 25th, 2024
- nmible partners with Velocity Clinical Research to streamline clinical trials patient stipends - January 25th, 2024
- Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets - January 25th, 2024
- Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment - January 25th, 2024
- Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products - January 25th, 2024
- AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced... - January 25th, 2024
- Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine... - January 25th, 2024
- OrphAI Therapeutics Announces Appointment of Jay Fine to Board of Directors - January 25th, 2024
- PharmAla receives new “MDXXF” ticker from FINRA for OTCQB Listing - January 25th, 2024
- Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards - January 25th, 2024
- CORRECTION -- Sirona Biochem Corporate Update January 2024 - January 25th, 2024
- 23andMe to Report FY2024 Third Quarter Financial Results - January 25th, 2024
- Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 25th, 2024
- Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux - January 25th, 2024
- AbSolutions Med, Inc. Receives FDA Breakthrough Device Designation for its REBUILD™ Bioabsorbable Abdominal Wall Closure Device - January 25th, 2024
- Revive Therapeutics Ltd. Announces Offering of Up to $3 Million - January 25th, 2024
- BioSenic presents new Phase 3 data on JTA-004 to treat severe osteoarthritis pain at the 2024 OARSI World Congress - January 25th, 2024
- Detailed Analysis of BEXMAB Data Provides Insights into Patient Profiles of Responding HMA-Failed MDS Population - January 25th, 2024
- Nicox Provides Fourth Quarter 2023 Financial and Business Highlights - January 25th, 2024
- Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance - December 22nd, 2023
- NightHawk Biosciences Announces Completion of Demonstration Run for a Top-Tier NIH and DTRA Funded Research University - December 22nd, 2023
- Apnimed Announces First Patient Dosed in SynAIRgy, the Second Phase 3 Clinical Study of AD109, a Potential Nighttime Oral Treatment for Obstructive... - December 22nd, 2023
- IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial - December 22nd, 2023
- Cytek® Biosciences Introduces the Cytek Orion™ Reagent Cocktail Preparation System, the First-of-its-Kind Automated Cocktail Preparation Instrument... - December 22nd, 2023
- Panbela Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $2.0 Million Gross Proceeds Priced... - December 22nd, 2023
- Mithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA® in Israel - December 22nd, 2023
- CARBIOS publishes its second sustainability report and confirms its ambitions to accelerate the circular economy for plastic - December 22nd, 2023
- Hyloris Broadens Pipeline with new Product Candidate in Burning Mouth Syndrome - December 22nd, 2023
- Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option - December 22nd, 2023
- Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension - December 22nd, 2023
- Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis - December 22nd, 2023
- Seer to Present at the J.P. Morgan 42nd Annual Health Care Conference - December 22nd, 2023
- Lexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare Conference - December 22nd, 2023
- Evaxion Biotech Announces Closing of Private Placement - December 22nd, 2023
- Lowell Farms Inc. Announces Resignation of Board Member Brian Shure - December 22nd, 2023
- MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of... - December 22nd, 2023
- Polaris Group Announced the Acquisition of Genovior Biotech, Initiating Dual-Engine Growth - December 22nd, 2023
- Zealand Pharma enters into EUR 90 million finance agreement with the European Investment Bank - December 22nd, 2023
- Mendus announces clinical pipeline update - December 22nd, 2023
- Result of AGM - December 5th, 2023
- Omega Therapeutics to Participate in the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference - December 5th, 2023
- RetinalGeniX Technologies Inc. Appoints Dessy Boneva, MD, FACS to the Board of Directors - December 5th, 2023